ABSTRACT
Introduction
Esophageal cancer is the fourth leading cause of cancer-related mortality in Brazil 1 . The main histological type is squamous cell carcinoma, comprising about 90% of all esophageal carcinomas in our country 1 . The diagnosis is usually made at advanced stages, which explains the high mortality rate 2 .
The survival of patients with esophageal cancer submitted to surgery has been widely evaluated [3] [4] [5] [6] [7] , but few studies have investigated the clinical evolution of patients with advanced esophageal cancer 8, 9 .
Recent reports have demonstrated that systemic inflammation, expressed by high levels of serum-C reactive protein can predict the survival of patients with cancer [10] [11] [12] . The Glasgow
Prognostic Score is an inflammation-based prognostic score used as a predictive index of survival for patients with advanced cancer, including gastrointestinal carcinomas 12 . It is a simple prognostic indicator based on the serum levels of albumin and C reactive protein.
It is calculated as follows: a score of 0 for normal C reactive protein and albumin levels, score 1 for either an abnormal C reactive protein or abnormal albumin level and score 2 for both abnormal C reactive protein and abnormal albumin levels 11 .
The aim of this retrospective study was to evaluate the usefulness of the Glasgow Prognostic Score as a predictive factor of survival in a cohort of patients with advanced esophageal squamous cell carcinoma under palliative clinical care.
Methods

This study was approved by the Research Ethics
Committee of Botucatu Medical School, UNESP. Sector. The obtained values were compared to the reference data.
5. The Glasgow Prognosis Score (GPS) was based on the serum levels of albumin and C-reactive protein (CRP) 11 . It was calculated as follows: Patients with both normal CRP (≤1.0mg/ dL) and albumin (≥3.5mg/dL) levels were allocated a score of 0.
Patients with either an abnormal C reactive protein or abnormal albumin level were allocated a score of 1 and patients with both an elevated CRP (>1.0 mg/dL) and hypoalbuminemia (<3.5mg/dL)
were allocated a score of 2.
6. Tumor site and histopathology were determined by endoscopic evaluation and biopsy reports.
Clinical Tumor Staging was performed based on tomographic exams of the thorax and abdomen (TNM/ UICC
classification -National Cancer Institute, 2012).
Survival rate was evaluated considering the time
between endoscopic diagnosis and patient death or last interview.
Results
Demographics
The study included 50 patients with advanced esophageal squamous cell carcinoma stages III and IV, under palliative clinical care. The demographics are summarized on Table 1 . Forty eight patients were male (96%) and 2 female, aged 38-81 years (median age 60.9 years). 56% of the studied population was older than 60. and all had 12-month survival (p<0.6).
Nutritional condition
The Glasgow Prognosis Score (GPS)
GPS of 0, 1 and 2 were observed in seven, 23 and 20
patients, respectively (Table 1) . A significant inverse relationship was observed between GPS scores and the survival rate (p<0.001, Table 3 ). The survival rate was greatest in patients with GPS= 0 (20.5 ± 8.8 months) and significantly higher (<0.001) than those from patients with GPS=1 (8.8 ± 5.5 months) and GPS=2 (3.2± 2.5).
Minimum 12-month survival was observed in 71%
patients with GPS=0 and in 30% patients with GPS=1. None of the patients with GPS=2 survived for 12 months (p<0.001, Table 4 ).
Serum albumin
Serum albumin levels ranged from 1.6 to 4.8 mg/dL, with a mean of 3.4 ± 0.7 mg/dL (Table 1 ). Fifty percent of the patients presented normal serum albumin levels. A significant relationship was observed between serum albumin levels and the survival rate (p<0.001, Table 2 ). Forty percent of the patients with normal albumin levels survived for at least 12 months, while only 4% of the patients with low albumin levels survived for 12 months (p<0.006, Table 4 ).
C Reactive Protein (CRP)
Serum-C reactive protein levels ranged from 0. Table 4 ).
Tumor site
Endoscopically, the tumor was located in the middle third of the esophagus in the majority of patients (n=30). Tumor was in the upper (n=10) or at the distal third of the esophagus in 10 patients (p<0.0001). Survival rate did not differ significantly in relation to tumor site (Table 4) .
Staging
Most patients (n=35) were in stage IV (T x N x M 1 ) and 15 patients were in stage III (T 3 N 1 M 0 ) (p<0.0001). There were no significant differences on the 12-month survival rates between patients in stages III and IV (Table 4 
Discussion
This study investigated the usefulness of the Glasgow Prognostic Score, which is an inflammation-based prognostic score, to predict survival in a cohort of patients with advanced esophageal squamous cell carcinoma under palliative clinical care.
The high incidence of advanced esophageal cancer in male patients (96%) observed in our study has been reported in other studies 3, 15, 16 . Patient mean age (60 ± 10 years old) in our series of cases was lower than that reported by Ando et al. 7 and
Eloubeidi et al.
17
. Considering that cancer patients are in a chronic inflammation condition 20 , the Glasgow Prognostic Score has been used to classify the degree of inflammation based on the serum levels of C reactive protein and albumin [10] [11] [12] 18 .
In the present study we have evaluated the Glasgow Prognostic Score (GPS) in a homogeneous population of fifty patients with advanced esophageal squamous cell carcinoma submitted only to palliative clinical treatment, gastrostomy or jejunostomy, in association with chemotherapy and radiotherapy.
Global patient survival in our study was 8.2 ± 7.6 months. It is similar to that reported in patients with advanced esophageal cancer submitted to two types of palliative treatment, self expandable metallic stent or isoperistaltic gastric tube 21 .
However, when the GPS score was considered, a significant inverse relationship was observed between GPS scores and the survival rate (p< 0.001). The survival rate was greatest in patients with GPS= 0 (20.5 ± 8.8 months) and significantly higher (< 0.001) than those from patients with GPS= 1 (8.8 ± 5.5 months) and GPS=2 (3.2± 2.5 months). We have observed that 71% patients with GPS = 0 survived for at least 12 months, while 30%
of patients with GPS=1 and none of the patients with GPS=2
survived for 12 months (p<0.001, Table 4 ). Our results on patient survival are higher than those reported by Crumley et al. 22 and
Silva et al.
18
.
In our study, the majority of patients (n=43) had a GPS of 1 and 2 than a GPS = 0 (n=7), which matches with the advanced 15 .
Out of the 50 patients analyzed, 30 had the tumor in the middle third of the esophagus,10 in the upper and 10 in the lower third of the esophagus. The preferential tumor site observed in our study is similar to the reported by most authors 3, 5, 7 . As expected, there were no relationship between tumor site and patient survival.
As to staging, most patients in this series (70%) were in stage IV and the others were in stage III (30%). The 12-month patient survival of the two groups did not differ significantly (p=0.7). This result was not surprising since both groups were in advanced stages of the disease.
In the present study most patients (n=41) presented high values of C reactive protein and from these only five patients survived for at least 12 months (p<0.001, Table 2 ). This finding highlights the sensitivity of this biomarker of inflammation to predict survival in patients with cancer, as previously reported 8, 15, 23 .
Interestingly, half of the patients (n=25) with advanced esophageal cancer presented normal albumin levels and from these, 40% patients survived for at least 12 months, while only 4% of the patients with low albumin levels survived for 12 months (p<0.006, Table 4 ). These results emphasize that albumin concentrations on its own are associated with survival in cancer patients 24 .
Conclusion
The Glasgow Prognostic Score (GPS), which is based on the serum levels of C reactive protein(CRP) and albumin, is an useful prognostic factor of survival for patients with advanced esophageal squamous cell carcinoma. Considering the low cost and the availability of C reactive protein and albumin testing, we recommend the use of the GPS score as a routine evaluation procedure to predict survival in patients with advanced esophageal cancer.
